European Union

EPO Patent EP4499128A1: Ligand Potentiation Methods

The European Patent Office published patent application EP4499128A1 on March 18, 2026, detailing methods and compositions for ligand potentiation. The patent lists Mark W. Grinstaff, Jack R. Kirsch, and Amanda K. Williamson as applicants and inventors.

Rutgers Patent EP4493705A1 for Gene Delivery

The European Patent Office has published patent EP4493705A1 for Rutgers, the State University of New Jersey, concerning controlled muscle-specific gene delivery. The patent was published on March 18, 2026, and lists Rutgers as the applicant.

EPO Patent EP4499055A2: Abietanes and Methods of Making and Using

The European Patent Office has published patent application EP4499055A2 concerning abietanes and methods of making and using them. The patent application was published on March 18, 2026, with The Florida State University Research Foundation, Incorporated listed as the applicant.

EPO Patent Publication EP4630420A1 on NLRP3 Inhibitors

The European Patent Office has published patent application EP4630420A1 concerning inhibitors of NLRP3, with F. Hoffmann-La Roche AG listed as the applicant. This publication details potential new therapeutic compounds and their applications.

EPO Patent Application: Pharmaceutical Formulation with Echinochrome A Nanofibers

The European Patent Office has published a new patent application, EP4629966A1, concerning a pharmaceutical formulation incorporating echinochrome A within polymeric micro/nanofibers. The application was published on March 18, 2026, and lists the National and Kapodistrian University of Athens as the applicant.

Therapeutic Agent for Respiratory Disease Patent EP4501326A1

The European Patent Office published patent application EP4501326A1 concerning a therapeutic agent for respiratory disease on March 18, 2026. The patent application lists The Jikei University and KOWA COMPANY, LTD. as applicants.

EPO Patent Publication: Adipic Acid Salt Form CCR6 Antagonist

The European Patent Office has published patent application EP4630118A1 concerning a crystalline adipic acid salt form of a CCR6 antagonist. The patent lists Idorsia Pharmaceuticals Ltd as the applicant and includes specific inventors and IPC classifications related to pharmaceutical compounds and their therapeutic uses.

EPO Patent Application: Modulating KRAS(G12D) Compositions

The European Patent Office has published patent application EP2024044334A2 by Ranok Therapeutics (Hangzhou) Co. Ltd. concerning methods and compositions for modulating KRAS(G12D). The publication date is March 18, 2026.

Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds

Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds

EPO Patent Publication EP4493556A1: NLRP3 Modulators

The European Patent Office (EPO) published patent application EP4493556A1 on March 18, 2026, related to NLRP3 modulators. The patent application lists Zomagen Biosciences Ltd as the applicant.